Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the second quarter ended September 30, 2021. For the second quarter, the company reported sales was INR 247.02 million compared to INR 253.58 million a year ago. Revenue was INR 249.19 million compared to INR 254.96 million a year ago. Net loss was INR 93.61 million compared to INR 38.66 million a year ago. Basic loss per share from continuing operations was INR 2.17 compared to INR 0.9 a year ago. Diluted loss per share from continuing operations was INR 2.17 compared to INR 0.9 a year ago.